Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethinylestradiol
- Development stage
- Unknown
- Lead developer
- Ace Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acelyn is an oral formulation of ethinylestradiol, a synthetic estrogen derivative of estradiol. Developed and marketed by Ace Pharmaceuticals, Acelyn is approved in the Netherlands for growth inhibition in girls with constitutional tall stature to limit their final adult height. Ethinylestradiol acts as a potent agonist of the estrogen receptors (ER-alpha and ER-beta), mimicking the physiological effects of endogenous estrogens. By promoting the early closure of the epiphyseal growth plates in the long bones, it effectively restricts further linear growth in adolescent girls.
- Brand names
- Acelyn
- Other names
- 17alpha-ethinylestradiol17alpha-ethynylestradiolethinyl estradiolethinyloestradioletinilestradiol
02
Targets
ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on ethinylestradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethinylestradiol.